For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Kyowa Pharma Hit by Biz Suspension over Manufacturing Flaws, Record Fabrications
March 29, 2022
- Asahi Kasei’s Recomodulin Enters US-Japan PI Study for Chemotherapy-Induced Peripheral Neuropathy
March 29, 2022
- Yakult Honsha Files Blood Cancer Med Duvelisib in Japan
March 25, 2022
- Shionogi Seeks Japan Approval of Novel Antibiotic Cefiderocol
March 25, 2022
- Towa Wins Livalo Damage Suit; Kowa to Appeal Ruling
March 25, 2022
- Fujifilm to Snap Up US Recombinant Protein Manufacturer
March 24, 2022
- Ube Grants Global Rights for CDK7 Inhibitor to Kirilys
March 24, 2022
- Chugai to Scale Down Wholesale Promotion Spend as Portfolio Pivots to Specialty Care: CEO
March 24, 2022
- Lecanemab Scores Positive Results in PIIb Study: Eisai/Biogen
March 23, 2022
- Sales Reps’ Online Detailing Activities Log Double-Digit Rise MOM, YOY in January: Intage
March 23, 2022
- Vectibix/Chemo Extends OS in 1st Line Colorectal Cancer: Japan PIII
March 22, 2022
- Sanofi Files PD-1 Drug Cemiplimab for Cervical Cancer in Japan
March 22, 2022
- Generic Makers, PMDA Exploring GMP Inspection Methods for Overseas Sites; Onsite Checks Not Possible for 2 Years
March 18, 2022
- Chugai Aspires to Grow Beyond 1 Trillion Yen Company: CEO
March 18, 2022
- Biogen Unveils Peer-Reviewed Aduhelm Data 9 Months after FDA OK
March 18, 2022
- Kenei, Maruho Settle Healmild Dispute; Brand Name to Remain with Design Changes
March 18, 2022
- Kyorin Grants Chinese Rights for Lascufloxacin to Local Company
March 18, 2022
- Chugai, Alexion Settle Patent Suits over Ultomiris
March 18, 2022
- FDA Clears Shionogi’s COVID-19 Pill for Global PIII Study
March 17, 2022
- Aduhelm Deal Revised, Eisai Poised to Sharpen Focus on Lecanemab: CEO
March 17, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…